

## CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Shah R. Makujina  
Type or print name

Signature

3/5/2004  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
CHATURVEDULA ET AL.

APPLICATION NO: 10/729,155

FILED: DECEMBER 5, 2003

FOR: CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references are of record in parent Application No. 10/445,523 filed May 27, 2003, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

Also, copies of the other cited references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(203) 677-7268

Shah R. Makujina  
Attorney for Applicants  
Reg. No. 41,174

Date: 3/5/2004

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)



ATTY. DOCKET NO.

CT2777A

APPLICATION NO.

10/729,155

APPLICANT

CHATURVEDULA ET AL.

FILING DATE

DECEMBER 5, 2003

Group

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	US 6,344,449 B1	2/5/02	Rudolf et al.			
	AB	US 6,552,043 B1	4/22/03	Patchett et al.			
	AC	US 6,521,609 B1	2/18/03	Doods et al.			
	AD	US 6,313,097 B1	11/6/01	Eberlein, et al.			
	AE	US 2003/0181462	9/25/03	Doods, et al.			
	AF	US 2003/0191068	10/9/03	Trunk, et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AG	WO 01/25228 A1	4/12/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AH	WO 99/52875	10/21/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AI	WO 01/32649A1	5/10/01	PCT [CA 2387613 English equiv]			<input type="checkbox"/>	<input type="checkbox"/>
	AJ	WO 00/55154	9/21/00	PCT [US 6,313,097 English equiv]			<input type="checkbox"/>	<input type="checkbox"/>
	AK	WO 98/11128	3/19/98	PCT [U.S. 6,344,449 English equiv]				
	AL	WO 00/18764	4/6/00	PCT				
	AM	WO 01/32648 A1	5/10/01	PCT				
	AN	WO 98/56779	12/17/98	PCT				
	AO	WO 98/09630	3/12/98	PCT				
	AP	WO 97/09046	3/13/97	PCT				
	AQ	WO 03/027252 A2	4/3/03	PCT				
	AR	WO 01/49676 A1	7/12/01	PCT [CA 2395541 English equivalent]				
	AS	WO 03/076432	9/18/03	PCT [no English equivalent]				


**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.

CT2777A

APPLICATION NO.

10/729,155

APPLICANT

CHATURVEDULA ET AL.

FILING DATE

DECEMBER 5, 2003

Group

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	HALL, et al., "Interaction of human adrenomedullin 13-52 with calcitonin gene-related peptide receptors in the microvasculature of the rat and hamster," <u>British Journal of Pharmacology</u> , 1995, 114, 592-597
2AB	HALL, et al., "Interaction of amylin with calcitonin gene-related peptide receptors in the microvasculature of the hamster cheek pouch <i>in vivo</i> ," <u>British Journal of Pharmacology</u> , 1999, 126, 280-284
2AC	DOODS, et al., "Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist," <u>British Journal of Pharmacology</u> , 2000, 129, 420-423
2AD	CHU, et al., "The calcitonin gene-related peptide (CGRP) antagonist CGRP8-37 blocks vasodilatation in inflamed rat skin: involvement of adrenomedullin in addition to CGRP," <u>Neuroscience Letters</u> , 310, 2001, 169-172
2AE	WILLIAMSON, et al., "Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat-intravital microscope studies," <u>Cephalalgia</u> , 1997, 17, 525-531
2AF	ESCOTT, et al., "Effect of a calcitonin gene-related peptide antagonist (CGRP8-37) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve," <u>British Journal of Pharmacology</u> , 1993, 110, 772-776
2AG	ESCOTT, et al., "Trigeminal ganglion stimulation increases facial skin blood flow in the rat: a major role for calcitonin gene-related peptide," <u>Brain Research</u> , 669, 1995, 93-99
2AH	WILLIAMSON, et al., "Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat," <u>Cephalalgia</u> , 1997, 17, 518-524
2AI	DE VRIES, et al., "Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy," <u>European Journal of Pharmacology</u> , 375, 1999, 61-74
2AJ	SHEN, et al., "Functional role of $\alpha$ -calcitonin gene-related peptide in the regulation of the cardiovascular system," <u>Journal of Pharmacology and Experimental Therapeutics</u> , 2001, 298, 2, 551-558
2AK	LASSEN, et al., "CGRP may play a causative role in migraine," <u>Cephalalgia</u> , 2002, 22, 54-61
2AL	ASHINA, et al., "Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks," <u>Pain</u> , 86, 2000, 133-138
2AM	GALLAI, et al., "Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally," <u>Cephalalgia</u> , 1995, 15, 384-390
2AN	GOADSBY, et al., "Vasoactive peptide release in the extracerebral circulation of humans during migraine headache," <u>Annals of Neurology</u> , 1990, 28, 2, 183-187

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.

CT2777A

APPLICATION NO.

10/729,155


APPLICANT

CHATURVEDULA ET AL.

FILING DATE

DECEMBER 5, 2003

Group

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

3AA	GRANT, et al., "Evidence of a role for NK1 and CGRP receptors in mediating neurogenic vasodilatation in the mouse ear," <u>British Journal of Pharmacology</u> , 2002, 135, 356-362
3AB	WILLIAMSON, et al., "Neurogenic inflammation in the context of migraine," <u>Microscopy Research and Technique</u> , 2001, 53, 167-178
3AC	EDVINSSON, "Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache," <u>CNS Drugs</u> , 2001, 15, 10, 745-753
3AD	BRAIN, et al., "CGRP receptors: a headache to study, but will antagonists prove therapeutic in migraine?," <u>Trends in Pharmacological Sciences</u> , 2/2002, 23, 51-53
3AE	JUANEDA, et al., "The molecular pharmacology of CGRP and related peptide receptor subtypes," <u>Trends in Pharmacological Sciences</u> , 11/2000, 21, 432-438
3AF	POYNER, et al., "Pharmacological characterization of a receptor for calcitonin gene-related peptide on rat, L6 myocytes," <u>Br. J. Pharmacol</u> , 1992, 105, 441-447
3AG	VAN VALEN, et al., "Calcitonin gene-related peptide (CGRP) receptors are linked to cyclic adenosine monophosphate production in SK-N-MC human neuroblastoma cells," <u>Neuroscience Letters</u> , 1990, 119, 195-198
3AH	EVANS, et al., "CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors," <u>Journal of Biological Chemistry</u> , 2000, 275, 409, 31438-31443
3AI	MCLATCHIE, et al., "RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor," <u>Nature</u> , 1998, 393, 333-339
3AJ	MALLEE, et al., "Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists," <u>Journal of Biological Chemistry</u> , 2002, 277, 16, 14294-14298
3AK	AMARA, et al., "Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products," <u>Nature</u> , 1982, 298, 240-244
3AL	
3AM	
3AN	

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.